sur CS MEDICA (isin : DK0061668225)
CS MEDICA A/S Positioned for Strong Growth in Alternative Medicine Market
CS MEDICA, a Danish Med-Tech firm, has initiated with a "Buy" rating by NuWays AG, citing its innovation in CBD-infused medical devices. The company focuses on developing treatments for conditions like arthritis, stress, and hair loss. Their products, backed by clinical trials, are positioned in major markets such as the EU, U.K., and U.S.
The firm employs a capital-light model, emphasizing research and distribution, while outsourcing manufacturing. This approach helps minimize operational risks. Notably, CS MEDICA is one of the few companies registered to sell CBD devices in pharmacies, uniquely bridging pharmaceutical and cosmetic markets.
As global demand for alternative medicine grows, projected at a 15.7% CAGR until 2031, CS MEDICA stands to benefit significantly. Their private-label segment provides stable revenues, supporting the expansion of their CANNASEN® brand. Market projections expect a top-line growth to DKK 108m by FY 2027/28, driven by a 61% CAGR.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CS MEDICA